Maynard Um
-
-
-
-
-
-
-
Glass Lewis backs Pacira BioSciences director nominees
-
-
-
-
-
-
-
RBC Capital Reiterates Sector Perform Rating on Pacira Pharmaceuticals (PCRX)
-
-
-
-
-
-
-
Pacira BioSciences reports $726.4 million revenue for 2025
-
-
-
-
-
-
-
Pacira BioSciences faces generic challenge to EXPAREL drug
-
-
-
-
-
-
-
PHARMACORP RX (PCRX) to acquire PharmaChoice Canada business in Western Canada for $2.4 million
-
-
-
-
-
-
-
Pacira Pharmaceuticals (PCRX) PT Raised to $26 at RBC Capital
-
-
-
-
-
-
-
FINAL REMINDER PCRX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Pacira BioSciences, Inc. Investors to Participate in the Class Action Lawsuit
-
426,916 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

